The company plans to develop a liquid biopsy assay that can identify patients most likely to benefit from treatment with checkpoint inhibitors.
The technology, which is patent pending, can be used to help identify cancer patients who would respond to immune checkpoint inhibition treatment.
The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.
The company has been working with NGS-based ctDNA testing for some time in research, but has now made its first move into the clinical sphere.
The Johns Hopkins University spinout has shifted from being research-oriented to focusing on bringing clinical tests through regulatory requirements.
The companies will work together to develop two next-generation sequencing-based in vitro cancer diagnostics.
In addition to its clinical trials matchmaking service, Cure Forward offers a platform for cancer patients to access and share their genomic test data.
The company said it anticipates rapid growth and intends to move to a new Baltimore facility in 2016.
The convertible note funding is part of a larger Series A round currently underway.
Despite the findings of the Hopkins study, for practical and economic reasons many diagnostic laboratories currently only sequence tumor samples or do not believe the tumor-normal approach is necessary.
Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.
Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.
The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.
In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.